P1.15-02 Migration Differences in Small Cell vs Non-Small Cell Lung Cancer
نویسندگان
چکیده
منابع مشابه
Clinicopathological Features of Patients with Non-small-cell Lung Cancer in West of Iran
Background: Lung cancer is the most common cause of cancer death worldwide with an annual mortality rate of more than 1.3 million worldwide. We aimed to analyze the clinicopathological features of patients with non-small-cell lung cancer (NSCLC) in west of Iran. Methods: 64 patients with NSCLC who referred to our clinic were analyzed. Sex, age, histopathology, location of the tumor, treatment,...
متن کاملSentinel Node Mapping in Non-small Cell Lung Cancer Using an Intraoperative Radiotracer Technique
Objective(s): Lymph node metastases are the most significant prognostic factor in localized non-small cell lung cancer (NSCLC). Identification of the first nodal drainage site (sentinel node) may improve detection of metastatic nodes. Extended surgeries, such as lobectomy or pneumonectomy with lymph node dissection, are among the therapeutic options of higher acceptab...
متن کاملATM induces radioresistance of non-small cell lung cancer A549 cells by downregulation of MDMX
Background: Tumor radioresistance leads to a reduction in the efficiency of radiation therapy. It is very important to explore the cellular mechanisms leading to radioresistance and to find potential therapeutic targets, which might improve the efficacy of radiation therapy. This study was to investigate the role of ataxia-telangiectasia mutated (ATM) and murine double minute X (MDMX) in radior...
متن کاملNon Small Cell Lung Cancer
H Endon et al (JCO 2004;22:811-9). Selected 8 genes out of 44 detected as prognostic markers of adenocarcinoma (Garber et al PNAS USA 98;13784-9, 2001 and Bhattachorjee et al PNAS USA 98;13790-5, 2001): PTK 7 (HR 0.5), CIT (HR 0.6), SCNNIA (HR 1.7), PGES (HR 2.2), EST-LB4D (HR 1.9), ERO 1l (HR 0.2), EST-AA434256 (HR 0.4) and ZWINT (HR 2.3). Low risk group had a 85% 5 y OS and high risk 40% 5 y OS.
متن کاملNon-Small Cell Lung Cancer
Downloa development of molecular markers is crucial for improving therapy in advanced non-small cell ancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, articular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, with p validation, and clinical application to different types of tissue specimens are discussed. Clin ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2018
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2018.08.934